We understand the importance of developing new vehicles to efficiently package and deliver therapeutic agents, providing access to druggable and undruggable targets while avoiding immune reactions and degradation mechanisms. This necessity for effective drug delivery motivates the development of Vesigen’s revolutionary ARMMs technology, a class of extracellular vesicles that allows for novel therapeutic paradigms in hard-to-reach tissue types.
With a seasoned team, we intend to expediently advance our portfolio and to chart a clear path to the clinic. Our team has decades of experience leading drug discovery and development activities in preclinical and clinical settings. Supported by our top-tier investors and a prominent scientific advisory board, Vesigen is prepared to deliver on the promise of ARMMs therapeutics.
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
